News Sentiment

CYCN sentiment intelligence

Cyclerion Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.84 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 42

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+11.8% over one week, +18.0% over four weeks, trend active, and materially above fair value.

Latest direct headline Negative

Cyclerion Therapeutics (CYCN) Edges Lower, Testing Key Support Amid Low Volume - New Highs New Lows

Market Reaction

Price moving ahead of tone

58/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction 11.8% Price confirming higher
Trend fit Trend active 18.0% over four weeks
Fair value 37.5% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 32
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 42
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 8
Market source 6
TradingView 4
timothysykes.com 3
TradingKey 2
Moomoo 2
simplywall.st 2
Sahm 2

Event Lens

What the news is about

Classified themes
Market update 24
Deals and strategy 15
Earnings 11

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 50
Stock Titan Direct company coverage

Cyclerion Therapeutics (NASDAQ: CYCN) to merge with Korsana in $380M financing deal

Cyclerion Therapeutics plans a reverse merger with privately held Korsana Biosciences, combined with a concurrent $380 million private placement. The new entity will focus on neurodegenerative diseases, particularly Alzheimer's, utilizing Korsana's THETA blood-brain barrier platf

Tone
Positive 68/100
Event
Deals and strategy
Published
10 Jul 2026 21:10
Source
Stock Titan
SEC.gov Direct company coverage

EDGAR Filing Documents for 0001193125-26-301054

This SEC filing details a Form 425 submission by Cyclerion Therapeutics, Inc., accessible via the EDGAR system. The filing, with accession number 0001193125-26-301054, was made on July 10, 2026, and includes numerous documents and graphic files related to prospectuses and communi

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 15:39
Source
SEC.gov
TradingView Direct company coverage

Enterprise value to revenue forward of Cyclerion Therapeutics, Inc. – NASDAQ:CYCN

The article focuses on the enterprise value to forward revenue metric for Cyclerion Therapeutics, Inc. (NASDAQ: CYCN). It presents this financial data point for the company. The content appears to be a financial data snippet from TradingView, part of a larger analysis tool.

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 22:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Cyclerion Therapeutics, Inc. – NASDAQ:CYCN

This article provides a brief snapshot of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) focusing on its forward price to sales metric. It highlights the company's financial data availability on TradingView, indicating no current trades and a closed market status. The content is prim

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 21:09
Source
TradingView
TradingView Direct company coverage

Cyclerion Therapeutics,Inc. Actuals & Estimates (NASDAQ:CYCN)

This article provides an overview of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) including its stock performance, market capitalization, and financial estimates. It highlights key financial data such as net income and EBITDA, and answers frequently asked questions regarding the c

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 20:41
Source
TradingView
TradingKey Direct company coverage

Cyclerion Therapeutics Inc (CYCN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey.com discusses Cyclerion Therapeutics Inc (CYCN) and its revenue breakdown. It notes that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page provides basic stock inf

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 01:10
Source
TradingKey
TradingKey Direct company coverage

Cyclerion Therapeutics Inc (CYCN) Valuation: PE, PB & Fair Value Analysis

Cyclerion Therapeutics Inc (CYCN) currently holds a valuation score of 8.51, positioning it 126th out of 388 companies in the Biotechnology & Medical Research industry. The company's P/E ratio stands at -2.44, indicating a significant deviation from its recent high and low P/E va

Tone
Neutral 50/100
Event
Market update
Published
16 Jun 2026 04:40
Source
TradingKey
Moomoo Direct company coverage

Cyclerion Therapeutics Company Profile & Introduction

This document provides a company profile and introduction for Cyclerion Therapeutics. Further details about the company's operations, financial health, or strategic initiatives would be found within the full content of such a profile.

Tone
Neutral 50/100
Event
Market update
Published
28 May 2026 00:10
Source
Moomoo
Stock Titan Direct company coverage

[10-Q] Cyclerion Therapeutics, Inc. Quarterly Earnings Report

Cyclerion Therapeutics reported a wider net loss of $3.2 million in Q1 2026 with no revenue, while operating expenses rose. The company faces a significant cash crunch, with funds expected to last only into Q3 2026, prompting substantial doubt about its ability to continue as a g

Tone
Negative 28/100
Event
Earnings
Published
12 May 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

FMR LLC holds 15.0% of Cyclerion Therapeutics (NASDAQ: CYCN) in Schedule 13G

FMR LLC has reported a 15.0% beneficial ownership stake in Cyclerion Therapeutics (NASDAQ: CYCN), as detailed in a Schedule 13G filing. The investment firm beneficially owns 649,547 shares of common stock as of April 30, 2026, with sole dispositive power. This includes holdings b

Tone
Neutral 50/100
Event
Deals and strategy
Published
07 May 2026 14:39
Source
Stock Titan
Sahm Direct company coverage

Are OGN, TBRG, CYCN Obtaining Fair Deals for their Shareholders?

Halper Sadeh LLC, an investor rights law firm, is investigating Organon & Co. (OGN), TruBridge, Inc. (TBRG), and Cyclerion Therapeutics, Inc. (CYCN) for potential violations of federal securities laws and breaches of fiduciary duties related to their recent or proposed transactio

Tone
Negative 34/100
Event
Market update
Published
04 May 2026 22:39
Source
Sahm
Quiver Quantitative Direct company coverage

CYCN | Cyclerion Therapeutics, Inc. Common Insider Trading

This page provides an overview of insider trading activity for Cyclerion Therapeutics, Inc. (CYCN), alongside other financial data. It indicates no recent insider trading by directors and management, and no congressional trading data for the ticker. The article also lists signifi

Tone
Neutral 50/100
Event
Market update
Published
03 May 2026 06:11
Source
Quiver Quantitative
Stock Titan Direct company coverage

Cyclerion Therapeutics (NASDAQ: CYCN) updates board, compensation and PIPE details

Cyclerion Therapeutics filed an amended annual report (10-K/A) to provide detailed disclosures on its board structure, executive compensation, and share ownership, which were previously omitted. The report highlights an independent chairman, three key board committees, and polici

Tone
Neutral 50/100
Event
Market update
Published
30 Apr 2026 12:39
Source
Stock Titan
Stock Titan Direct company coverage

CYCN SEC Filings - Cyclerion Therapeutics Inc 10-K, 10-Q, 8-K Forms

This page provides a comprehensive resource for investors and traders to access Cyclerion Therapeutics (CYCN) SEC filings, including annual reports (10-K), quarterly reports (10-Q), and material event reports (8-K). It details how these documents offer insights into the company's

Tone
Neutral 50/100
Event
Market update
Published
29 Apr 2026 08:40
Source
Stock Titan
HarianBasis.co Direct company coverage

Cyclerion Merges with Korsana to Develop Alzheimer Antibody Therapy

Cyclerion Therapeutics and Korsana Biosciences have merged to form a new entity, Korsana Biosciences (KRSA), focused on developing neurodegenerative disease treatments. The combined company will prioritize KRSA-028, a new antibody targeting amyloid beta for Alzheimer's disease, u

Tone
Positive 74/100
Event
Market update
Published
22 Apr 2026 12:09
Source
HarianBasis.co
Market source Direct company coverage

Cyclerion Therapeutics (CYCN) Merges With Korsana Biosciences to Advance Alzheimer’s Pipeline

Cyclerion Therapeutics (NASDAQ:CYCN) has merged with Korsana Biosciences to form a new entity, also named Korsana Biosciences, trading under the ticker 'KRSA'. The merger aims to advance Korsana's neurodegenerative pipeline, specifically targeting Alzheimer's disease with KRSA-02

Tone
Positive 70/100
Event
Deals and strategy
Published
20 Apr 2026 16:15
Source
Market source
Stock Titan Direct company coverage

Korsana deal gives investors control; Cyclerion to become Korsana Biosciences (CYCN → KRSA)

Cyclerion Therapeutics is merging with Korsana Biosciences, a privately held biotechnology company focused on neurodegenerative diseases. The merger will result in current Korsana shareholders owning approximately 98.5% of the combined company, which will be renamed Korsana Biosc

Tone
Neutral 50/100
Event
Deals and strategy
Published
17 Apr 2026 16:40
Source
Stock Titan
MSN Direct company coverage

Cyclerion Therapeutics stock soars 350% on Korsana merger, $380 million financing

Cyclerion Therapeutics (CYCN) went up 350% in after-hours trading following the announcement of its merger with Korsana, a private biotechnology firm. The combined entity, specializing in therapies for inflammatory, fibrotic, and renal diseases, will be capitalized with $380 mill

Tone
Neutral 50/100
Event
Deals and strategy
Published
14 Apr 2026 15:09
Source
MSN
Citeline News & Insights Direct company coverage

Finance Watch: Replimune Cutting Jobs As FDA Rejects RP1 A Second Time

Replimune is implementing job cuts after the FDA rejected its drug candidate, RP1, for a second time. This development is part of a broader "Finance Watch" update which also covers Cyclerion, Kezar, and IO Biotech exploring strategic alternatives. The recurring FDA rejection for

Tone
Neutral 50/100
Event
Market update
Published
10 Apr 2026 22:39
Source
Citeline News & Insights
PR Newswire Direct company coverage

Are UNF, NSA, CYCN, ULYX Obtaining Fair Deals for their Shareholders?

Halper Sadeh LLC, an investor rights law firm, is investigating UniFirst (UNF), National Storage Affiliates Trust (NSA), Cyclerion Therapeutics (CYCN), and Urgent.ly (ULYX) for potential violations of federal securities laws and breaches of fiduciary duties related to their propo

Tone
Negative 40/100
Event
Market update
Published
09 Apr 2026 19:09
Source
PR Newswire